
My Moinfo
<img alt="" height="1" width="1" />
Biogen Sinks as ALS Drug Fails to Show Efficacy in Trial
Bloomberg
Biogen Idec Inc. (BIIB) declined the most in almost two months after the third-biggest biotechnology company said its experimental drug for amyotrophic lateral sclerosis failed to help patients in a clinical trial. Biogen sank 1.4 percent to $147.86 at 4 p.m. New ...
Biogen Idec drops ALS drug dexpramipexolePMLiVE
Biogen Idec's ALS drug binned after failed trialPharmaTimes
Biogen Idec gives up on experimental drug to treat Lou Gehrig's diseaseBoston.com
RTT News -Medical News Today -iStockAnalyst
all 106 news articles »
More...